

# Is Supplemental O<sub>2</sub> a Good Supplement?

**Jeffrey M. Goodloe, MD, NRP, FACEP, FAEMS**

**Chief Medical Officer**

**EMS System for Metropolitan Oklahoma City and Tulsa**

**Professor & EMS Section Chief**

**University of Oklahoma School of Community Medicine**

**Medical Director - Oklahoma Highway Patrol**



# **DISCLOSURE** for Continuing Medical Education Purposes

- This activity has been planned and implemented in accordance with the accreditation requirements and policies of the *Accreditation Council for Continuing Medical Education (ACCME)* through the joint providership of White Coat Institute (d.b.a. *GetMyCME*) and the *Gathering of Eagles* alliance.
- The White Coat Institute is accredited by the ACCME to provide continuing medical education for physicians.
- None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

# **Additional DISCLOSURE in this case**


*for Continuing Medical Education Purposes ...*

It should be noted that **Dr. Goodloe** does have a consulting relationship with **J&J MedTech, Fisher & Paykel, Medtronic, & Purdue/Knoa Pharma**

However, this CME activity has been designed and reviewed by an independent committee with no relevant financial ties to ensure that the content is free of commercial bias and evidence-based. Accordingly, all of the relevant financial relationships listed for **Dr. Goodloe** have been mitigated.

# Seems Simple Enough...

- In 1976, EMTs were told that oxygen could not harm a critically ill injured patient in the short prehospital window. If a patient was sick enough to warrant transport, they were generally considered in need for oxygen.
- Pulse oximetry was a new invention not in widespread use – even in hospitals.





# Fortunately, We've Learned a Thing or More About More...

## ***OXIDATIVE STRESS***



Normal cell



Free radicals attacking cell



Cell with oxidative stress



# Avoiding Higher Pressures in “High Pressure” Situations



**Table 1** Mean Values (n = 8) for Cardiopulmonary Variables Using Various Rates of PPV in a Swine Model of Moderate, Controlled Hemorrhage

|                           | RR (breaths/min) |             |             |             |             |
|---------------------------|------------------|-------------|-------------|-------------|-------------|
|                           | 12               | 6           | 20          | 30          | 6           |
| RA (mm Hg)*               | 1 ± 1            | 0 ± 1       | 4 ± 1       | 5 ± 1       | 0 ± 1       |
| ITP (mm Hg)               | 15 ± 2           | 12 ± 2      | 16 ± 2      | 19 ± 2      | 11 ± 2      |
| Ao Syst (mm Hg)*          | 65 ± 2           | 84 ± 4      | 73 ± 4      | 66 ± 5      | 95 ± 6      |
| Ao Diast (mm Hg)          | 51 ± 2           | 71 ± 5      | 59 ± 4      | 52 ± 5      | 81 ± 6      |
| Pao <sub>2</sub> (mm Hg)  | 68 ± 4           | 138 ± 13    | 113 ± 7     | 115 ± 3     | 174 ± 20    |
| Paco <sub>2</sub> (mm Hg) | 35 ± 1           | 62 ± 2      | 28 ± 1      | 19 ± 1      | 58 ± 2      |
| pH (arterial)             | 7.46 ± 0.02      | 7.28 ± 0.02 | 7.51 ± 0.01 | 7.02 ± 0.02 | 7.28 ± 0.01 |
| CPP (mm Hg)               | 50 ± 2           | 60 ± 4      | 47 ± 3      | 42 ± 4      | 71 ± 6      |
| Qr (L/min)                | 2.4              | 2.8         | 2.5         | 2.4         | 3.0         |


RA, right atrial diastolic pressure; ITP, mean intrathoracic airway pressure; Ao Syst, aortic systolic pressure; Ao Diast, aortic diastolic pressure; Pao<sub>2</sub>, arterial oxygen tension; Paco<sub>2</sub>, arterial carbon dioxide tension; CPP, coronary perfusion pressure (averaged over 10 min); Qr, Cardiac output.

\* Measured at end-expiration.

**Pepe PE et al. Emergency Ventilatory Management in Hemorrhagic States: Elemental or Detrimental?. The Journal of Trauma: Injury, Infection, and Critical Care 54(6):p 1048-1057, June 2003. | DOI: 10.1097/01.TA.0000064280.05372.7C**



# *Breath by Breath Falls in Coronary Perfusion Pressure*



# It's All a Balanced Equation

- Get the patient back to “normal”
- Promote perfusion
- Avoid excessive partial pressures of O<sub>2</sub>
- Avoid excessive pressures in PPV



# TULSA



Contact Info:  
jeffrey-goodloe@ou.edu  
Office of the Medical Director  
www.okctulomd.com  
918-596-3147  
@drjeffgoodloe





# Oxygen and Outcomes in Acute Ischemic Stroke

DR. James Roach  
EMS Medical Director  
BSO, FLFR, SRFR

## **DISCLOSURE for Continuing Medical Education Purposes**

- **This activity has been planned and implemented in accordance with the accreditation requirements and policies of the *Accreditation Council for Continuing Medical Education (ACCME)* through the joint providership of White Coat Institute (d.b.a. *GetMyCME*) and the *Gathering of Eagles* alliance.**
- **The White Coat Institute is accredited by the ACCME to provide continuing medical education for physicians.**
- **None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.**

# Oxygen



IS HYPEROXYGENATION OXYGEN  
HARMFUL IN ACUTE ISCHEMIC  
STROKE PATIENTS?



IS HYPEROXYGENATION  
BENEFICIAL IN ACUTE ISCHEMIC  
STROKE PATIENTS?

# Oxygen

## In-hospital Management of AIS: General Supportive Care 4.3 Supplemental Oxygen

| Recommendations  | COR             | LOE  |
|--|-----------------|------|
| 1. Airway support and ventilatory assistance are recommended for the treatment of patients with acute stroke who have decreased consciousness or who have bulbar dysfunction that causes compromise of the airway. | I               | C-EO |
| 2. Supplemental oxygen should be provided to maintain oxygen saturation >94%.  | I               | C-LD |
| 3. Supplemental oxygen is not recommended in nonhypoxic patients hospitalized with AIS.  | III: No Benefit | B-R  |

# Oxygen Use in Acute Stroke

## Current AHA Guidelines

Does oxygen help or is it harmful?

Recommend O<sub>2</sub> Saturations between 94–98%.

Hyperoxia may cause oxidative damage?

Supplemental O<sub>2</sub> only if SpO<sub>2</sub> <94%

Recommendation: Avoid routine O<sub>2</sub> unless hypoxic?

# Randomized – Normoxemic Stroke (Non-EVT)

## Stroke Oxygen Study (SO<sub>2</sub>S) (JAMA 2017)

**Design & timing:** Multicenter, single-blind RCT; **8,003 adults with acute stroke**, randomized **within 24 h of hospital admission** across 136 UK centers. Arms: (1) **continuous O<sub>2</sub> for 72 h**, (2) **nocturnal O<sub>2</sub> only (21:00–07:00 for 3 nights)**, (3) **control (O<sub>2</sub> only if clinically indicated)**.

• **Dose & delivery:** Nasal cannula **3 L/min if SpO<sub>2</sub> ≤93%** or **2 L/min if >93%**.

• **Population:** Median NIHSS 5; **mean baseline SpO<sub>2</sub> ≈96.6%** (i.e., largely normoxic).

• **Primary outcome (mRS shift at 90 d):** **No difference** for pooled oxygen vs control (OR **0.97**, 95% CI 0.89–1.05) and **no difference** continuous vs nocturnal (OR **1.03**, 95% CI 0.93–1.13).

• **Safety/secondary:** **No significant harms**; serious AEs similar across groups. No subgroup with clear benefit identified.

• **Adherence/physiology notes:** The trial added midnight/6am spot checks in later enrollees; prior pilot signals didn't replicate, and **severe desaturations were not significantly different** between treatment and control.

### Practical takeaway

For **non-hypoxic** acute stroke patients, **routine low-dose oxygen (2–3 L/min) for 72h—continuous or nocturnal—does not improve 90-day death/disability and appears safe but unnecessary.**

Use oxygen **selectively**, e.g., when **SpO<sub>2</sub> <94–95%** or clinically indicated.

# Evolution of Normobaric Hyperoxia (NBO) in Acute Ischemic Stroke

## OPEN I: 2019

### Can Oxygen save brain tissue?

- Single center EVT, Randomized controlled
- 86 Randomized; 43 EVT alone & 43 NBO + EVT
- NRB 10L, 4 Hours
- 47% reduction in infarct Volume (20.1ml vs 37.7ml)
- mRS 90 Days: (NBO + EVT=2 ) vs (EVT Alone = 3)
- **Proof of Concept: Decrease Infarct Volume**

## Phase II: OPENS-2 Dose Finding (2024 – Stroke).

### How Much Oxygen exposure is needed?

- Multicenter EVT-era dose-finding trial.
- 10 L/min O<sub>2</sub> vs 1 L/min sham for 4 h post-EVT.
- 2H, **4H**, 6H duration of Oxygen, 72 H infarct volume
- 4H = Best outcomes, **50% reduction in infarct volume** vs control (19.7 ml vs 39.4ml) and no adverse effects
- Established safe, optimal dose for confirmatory trial.

## Phase III: OPENS-2 (2025 – Lancet) (Confirmatory Evidence)

### Does this translate into better patient outcomes?

- Multicenter RCT, 282 EVT-treated patients
- Randomized 10 L/min O<sub>2</sub> vs 1 L/min (sham) for 4 h post-EVT
- 4 Hour period, Peri-Thrombectomy
- **Improved 90-day mRS (median 2 vs 3) , 40% reduction in Infarct volume,**
- Mortality 10% vs 12%
- **No increase in ICH or oxidative injury**

# OPENS-2 trial (Li et al, *Lancet* 2025), Normobaric Hyperoxia combined with endovascular treatment for acute ischemic stroke in China— multicenter, randomized, single-blind, sham-controlled trial.

**Objective:** To test whether augmenting endovascular therapy (EVT) with normobaric hyperoxia (NBO) **improves 90-day functional outcomes, without compromising safety**, in patients with acute ischemic stroke from large-vessel occlusion in the anterior circulation.

## Design & Methods

- Multicenter (26 comprehensive stroke centers in China)
- Randomized 1:1, single-blind (patients + outcome assessors blinded) to:
  - **Intervention:**
    - **NBO arm: inhalation of 100% O<sub>2</sub> at 10 L/min via non-rebreather mask for 4 h (or FiO<sub>2</sub> = 1.0 if intubated)**
    - Sham arm: 100% O<sub>2</sub> at 1 L/min (i.e., low flow) → approx FiO<sub>2</sub> ~0.3
- **Inclusion:** age 18–80, within 6 h of onset, anterior-circulation large-vessel occlusion, eligible for EVT
- **Primary outcome:** distribution of modified Rankin Scale (mRS) scores at 90 days (ordinal shift) in intention-to-treat population
- **Safety:** mortality, serious adverse events, oxygen-related AEs

## Enrollment & Baseline Characteristics

- Screened: **473 patients** → **Randomized: 282 (140 NBO + EVT, 142 sham + EVT)**
- Median age: 65 years (IQR 57–71)
- Sex: 75 (27%) female, 207 (73%) male
- All participants were Han Chinese ethnicity

## Functional outcomes (90 days)

- Median mRS: 2 (IQR 1–4) in NBO group vs 3 (1–4) in sham group.
- **Overall a 1 point improvement in mRS for the Oxygen arm of the trial, 40% reduction in infarct volume**
- Adjusted common odds ratio (cOR) for better shift on mRS: 1.65 (95% CI 1.09 – 2.50),  $p = 0.018$
- **In other words, patients in the NBO + EVT arm had higher odds of a better outcome distribution.**

## Mortality & Safety

- **Deaths by 90 days: 14/140 (10%) in NBO vs 17/142 (12%) in sham;** adjusted risk difference (95% CI –0.09 to 0.06)
- **Serious adverse events: 28 (20%) in NBO vs 33 (23%) in sham;** adjusted risk difference (95% CI –0.12 to 0.07)
- **No significant increase in oxygen-related complications was reported.**

## Authors' Interpretation

NBO-augmented EVT yielded superior functional outcomes at 90 days (ordinal mRS shift) compared to sham, without a safety penalty. The authors suggest NBO may serve as a neuroprotective adjunct to EVT.

# Key Takeaways



## Oxygen in AIS:

Oxygen NRB 10L 4-hour duration peri EVT, MAY improve outcome

- mRS 90 days
- Decrease Infarct Volume

\* No RCT demonstrates harm from short-term O<sub>2</sub>.